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This article reports the clinical course and treatment of ocular adnexal lymphoma based on a retro-
spective review of ﬁve cases with a histologically approved ocular adnexal lymphoma at Kaohsiung
Veterans General Hospital over 10 years. Extranodal B-cell lymphoma in the orbit, lacrimal gland, eyelid,
or conjunctiva was found in these patients. Four of them were female, and they were aged 45e64 years.
All patients were also consulted with hematologists for possible systemic involvement and therapeutic
plan. The patient with retrobulbar and orbital apex involvement received systemic chemotherapy. The
patient with lacrimal gland involvement experienced tumor recurrence after local excision, and therefore
received adjuvant radiotherapy. The remaining three patients had localized lymphoma on the eyelid or
bulbar conjunctiva, and they all showed no recurrence after surgical excision. The incidence of ocular
adnexal lymphoma has risen worldwide over the last few decades. Although most cases are conﬁned to
ocular adnexal, some may also be associated with disseminated lymphoma. Accurate diagnosis and
staging is mandatory for appropriate treatment. Generally speaking, localized and low-grade ocular
adnexal lymphoma involved eyelid or conjunctiva seem to have good outcome after surgical excision
only. Systemic chemotherapy should be considered in patients with advanced disease or systemic
manifestations, and radiotherapy also offers a good choice for lacrimal gland lymphoma.
Copyright © 2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Lymphoma of the ocular adnexa is a heterogeneous group of
malignancies, accounting for approximately 1e2% of non-Hodgkin
lymphomas and 8% of extranodal lymphomas.1 In the recent past,
there have been signiﬁcant advances in our understanding of the
clinical characteristics, morphology and phenotype, etiology,
pathogenesis, diagnosis, natural history, treatment approaches,
outcome, and prognostic factors of this disease entity.
Ocular adnexal lymphomas are mostly seen in the 5th to 7th
decade of life with female predominance. The most frequently
involved site is the orbit (40%), followed by conjunctiva (35e40%),
lacrimal gland (10e15%), and eyelid (10%).2 A large majority of re-
ported cases correspond to the B-cell type, low-grade type andancial conﬂicts or interests in
any commercial or propriety
ology, Kaohsiung Veterans
813, Taiwan, ROC.
ciety of Taiwan. Published by Elsevlocalized disease (Stage I). Five cases of extranodal B-cell lymphoma
involved in different part of ocular adnexa are reviewed in this
article.2. Case reports
2.1. Case 1
A 49-year-old man presented with right proptosis with decreased
vision (VA:OD:CF/20cm;OS:6/5), limitedeyemovementandafferent
pupillary defect in the right eye (Fig. 1A). Orbital magnetic resonance
imaging revealed prominent retrobulbarmass involving apical region
in the right orbit (Fig. 1B and C). Orbitotomy was performed and the
histologic features of inferior orbital tissue demonstrated high-grade
extranodal marginal zone B-cell lymphoma. Neither laboratory anal-
ysis nor image study showed evidence of systemic involvement (Stage
IE). After discussion with hematologists, a combination regimen of
chemotherapy (cyclophosphamide, epirubicin, vincristine, and pred-
nisone) was applied. His symptoms improved signiﬁcantly without
complications in the following 5 years (Fig. 1D).ier Taiwan LLC. All rights reserved.
Fig. 1. (A) Case 1: severe exophthalmos, congestion and limited eye movement of the right eye was noted. (B,C) Orbital magnetic resonance imaging showed prominent retrobulbar
mass involving apical region in the right orbit causing marked exophthalmos. (D) Case 1 after combination regimens of chemotherapy.
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A 64-year-old woman was referred to our hospital due to right
eyelid swelling and drooping for 1 month. Ophthalmological ex-
amination revealed excellent visual acuity (6/6 in both eyes); the
anterior segment and fundi showed normal appearance. However,
a mass measuring 1.5 cm  1.0 cm was palpable in the right upper
lid (Fig. 2A). Right lacrimal gland tumor was noted from head and
neck computed tomography (CT; Fig. 2B). Based on the CT scan
ﬁnding, excisional biopsy was performed, and the pathology
revealed low-grade, extranodal marginal zone B-cell lymphomas of
mucosa-associated lymphoid tissue (MALT). The hematologist
suggested observation and follow-up. However, recurrent lid
swelling with proptosis was noted 6 months later. Recurrent lym-
phoma with involvement of the right lacrimal gland (Fig. 2C), right
parotid gland, pretracheal region, cervical, and mediastinal nodes
were found on CT scan (Stage II E). Since this was a low-grade
lymphoma, debulking of lacrimal gland tumor through right
anterior orbitotomy was performed. The patient also underwent
adjuvant radiotherapy to the residual tumor with 36 Gy in 18
fractions. There was no local recurrence in the following 6 months,
and systemic chemotherapy will be considered if high-grade
transformation of lymphoma occurs.
2.3. Case 3
A 62-year-old woman noted left lower lid palpable mass for 6
months (Fig. 3). She denied systemic disease or trauma history. The
ocular examinations showed normal anterior segment and fundi.
The result of excisional biopsy demonstrated low-grade, extranodal
marginal zone B-cell lymphomas of MALT. Laboratory data showednormal blood proﬁle, liver panel, and renal function. CT of head,
neck, and whole abdomen showed no evidence of systemic lym-
phoma (Stage IE). The postoperative condition was stable without
tumor recurrence in the following 6 months.
2.4. Cases 4 and 5
Two 45-year-old female patients presented with orangeered,
painless, and progressively enlarging masses over nasal bulbar
conjunctiva of the left eyes (Fig. 4A). The past medical history was
uneventful and particularly no B-symptoms were reported. The
ocular examinations were normal except for the conjunctival
masses. Both patients underwent excisional biopsy and the his-
tology also showed low-grade, extranodal marginal zone B-cell
lymphomas of MALT. Neither laboratory survey nor image study
showed evidence of systemic involvement (stage IE). The
conjunctival wounds healed well without tumor recurrence after 1-
year follow up postoperatively (Fig. 4B).
3. Discussion
Most ocular adnexal lymphomas are primary extranodal neo-
plasms. However, about 10e32% of patients have secondary tumors
with systemic lymphoma.3,4 The most common subtype is extra-
nodular marginal zone lymphoma of MALT (35e80%), followed by
follicular lymphoma (20%), diffuse large B-cell lymphoma (8%), and
less commonly mantle cell lymphoma, small lymphocytic lym-
phoma, and lymphoplasmacytic lymphoma.3,5 The initial evalua-
tion of these patients requires careful ophthalmic examination and
adequate tissue sampling for histopathological diagnosis. Further
assessments for accurate staging and therapeutic planning include
Fig. 2. (A) Case 2 at ﬁrst visit: right upper lid swelling with a palpable mass. (B) Head and neck computed tomography demonstrated a right lacrimal gland tumor. (C) The follow-up
computed tomography scan showed recurrent lymphoma involving the right lacrimal gland 6 months later.
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studies, serum protein electrophoresis, serum LDH, b2-
microglobulin, chest x-ray, bone marrow biopsy, CT of chest,
abdomen, and pelvis. Unfavorable prognostic features include
advanced stage,6 old age, nodal involvement,7 B symptoms (fever,
night sweats, and weight loss),8 performance status > 1, elevated
serum LDH or b2-microglobulin levels,9 and p53 gene expression.10
The treatment modalities for the patients with ocular adnexal
lymphoma include surgical resection, radiotherapy, single-agent or
combined regiments of chemotherapy, monoclonal anti-CD20
antibody, and interferon immunotherapy.11 Surgical resection is
indicated for encapsulated tumors but the risk of recurrence isFig. 3. Case 3: left lower lid mass was noted for 6 months.relatively high. Radiotherapy for localized MALT lymphoma in the
ocular adnexa offers excellent local control with a prolonged clin-
ical course.12 Systemic chemotherapy should be considered in pa-
tients with advanced disease or systemic manifestations. Blasi et al
suggested that local immunotherapy with IFN-a seems to be an
effective and lasting treatment method and provides an alternative
to radiotherapy for conjunctival MALT lymphomas.11
Antibiotic therapy for ocular adnexal lymphoma has also been
proposed. Ferreri et al reported that patients with ocular adnexal
lymphoma had a high prevalence of Chlamydia psittaci infection in
both tumor tissue and peripheral blood mononuclear cells.13 How-
ever, Chanudet et al reported that C. psittaci is variably associated
with ocular adnexal MALT lymphoma in different geographical re-
gions.14 Because of the variable prevalence of C. psittaci infection in
patients with ocular adnexal lymphoma, empiric antibiotic therapy
without prior testing cannot be generally recommended.15
The incidence of ocular adnexal lymphoma, particularly ocular
adnexal MALT lymphoma, has risen worldwide over the last few de-
cades. It may present on routine examination or with only mild sub-
jective symptoms.We retrospectively searched ourmedical record in
the last 10 years, and only found these ﬁve cases. Four of our cases
were low-grade and localized disease, which is comparable with
previous reports in the literature. All of our patients were diagnosed
by the initial and only presentation of ocular symptoms. Surgical
excision alone was performed on Cases 3, 4, and 5, and remained tu-
mor free for 6e12 months, but long-term follow-up is still needed.
In conclusion, no prospective clinical trials have been conducted
to deﬁne the optimal treatment approach for ocular adnexal lym-
phoma, and there are nouniversallyaccepted therapeutic guidelines.
The ﬁnal treatment decision requires a multidisciplinary approach,
taking into account the histopathological type, the extent of the
disease, the impact on the eye or visual function, and disease-related
Fig. 4. (A) Case 4: an orangeered, painless mass over nasal bulbar conjunctiva of the
left eye. (B) The conjunctival wound healed well without tumor recurrence after sur-
gical excision.
C.-L. Tsen et al. / Taiwan Journal of Ophthalmology 5 (2015) 99e102102prognostic factors.2 Although most cases of ocular adnexal lym-
phoma were primary extranodal neoplasm, they may also be asso-
ciatedwith disseminated lymphoma. Therefore, a rigorous approach
toaccuratediagnosis andsystemicstaging is fundamental foroptimal
treatment planning and outcome. From our limited cases, we
observed a trend that the conjunctival and eyelid lymphoma seemed
to have better outcome, but the ocular adnexal lymphoma involved
orbitsor lacrimalglanddemandsmorevigorous treatment.However,
this will need larger patients group to conﬁrm.References
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